Format

Send to

Choose Destination
Antiviral Res. 2016 Sep;133:218-222. doi: 10.1016/j.antiviral.2016.08.012. Epub 2016 Aug 13.

Treatment of Lassa virus infection in outbred guinea pigs with first-in-class human monoclonal antibodies.

Author information

1
Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston, Texas, USA.
2
Galveston National Laboratory, University of Texas Medical Branch at Galveston, Galveston, Texas, USA.
3
Zalgen Labs, LLC, Germantown, MD.
4
Viral Hemorrhagic Fever Program, Kenema Government Hospital, Kenema, Sierra Leone.
5
Ministry of Health and Sanitation, Freetown, Sierra Leone.
6
Polytechnic College, Kenema Sierra Leone.
7
Sections of Infectious Disease, Departments of Pediatrics and Internal Medicine, School of Medicine, Tulane University, New Orleans, LA.
8
Department of Microbiology and Immunology, Tulane University, New Orleans, Louisiana, USA.
#
Contributed equally

Abstract

Lassa fever is a significant health threat to West African human populations with hundreds of thousands of annual cases. There are no approved medical countermeasures currently available. Compassionate use of the antiviral drug ribavirin or transfusion of convalescent serum has resulted in mixed success depending on when administered or the donor source, respectively. We previously identified several recombinant human monoclonal antibodies targeting the glycoprotein of Lassa virus with strong neutralization profiles in vitro. Here, we demonstrate remarkable therapeutic efficacy using first-in-class human antibodies in a guinea pig model of Lassa infection thereby presenting a promising treatment alternative.

PMID:
27531367
PMCID:
PMC5032844
DOI:
10.1016/j.antiviral.2016.08.012
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center